Dianthus Therapeutics (NASDAQ:DNTH) Research Coverage Started at Roth Capital

Roth Capital assumed coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report published on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $113.00 price objective on the stock.

Other equities research analysts have also recently issued reports about the company. HC Wainwright reissued a “buy” rating and issued a $158.00 price objective on shares of Dianthus Therapeutics in a research report on Thursday, October 15th. JPMorgan Chase & Co. started coverage on shares of Dianthus Therapeutics in a research report on Friday, September 11th. They set an “overweight” rating and a $135.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Thursday, October 15th. Truist Financial boosted their price target on Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Finally, Citigroup assumed coverage on Dianthus Therapeutics in a research note on Friday, September 4th. They issued a “buy” rating and a $156.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $128.54.

Dianthus Therapeutics Trading Up 0.5%

Shares of NASDAQ:DNTH opened at $82.70 on Tuesday. The firm has a fifty day moving average price of $93.30 and a 200 day moving average price of $84.39. Dianthus Therapeutics has a 1 year low of $32.28 and a 1 year high of $117.88. The stock has a market capitalization of $4.53 billion, a PE ratio of -19.93 and a beta of 1.35.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. On average, sell-side analysts forecast that Dianthus Therapeutics will post -3.81 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Dianthus Therapeutics news, Director Anne McGeorge sold 7,750 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $109.01, for a total transaction of $844,827.50. Following the completion of the sale, the director owned 1,250 shares in the company, valued at approximately $136,262.50. The trade was a 86.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Edward Carr sold 20,000 shares of the company’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $101.38, for a total value of $2,027,600.00. Following the completion of the sale, the chief accounting officer owned 20,000 shares of the company’s stock, valued at $2,027,600. This represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 242,429 shares of company stock valued at $26,118,913 over the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Institutional Investors Weigh In On Dianthus Therapeutics

Hedge funds have recently bought and sold shares of the company. ABS Investment Management LLC bought a new position in Dianthus Therapeutics in the second quarter valued at approximately $194,960,000. PNC Financial Services Group Inc. boosted its position in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after purchasing an additional 139 shares during the last quarter. GAMMA Investing LLC increased its holdings in Dianthus Therapeutics by 83.6% during the third quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock worth $49,000 after buying an additional 254 shares during the last quarter. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics in the 1st quarter valued at about $32,000. Finally, Nisa Investment Advisors LLC raised its stake in Dianthus Therapeutics by 75.0% in the third quarter. Nisa Investment Advisors LLC now owns 1,057 shares of the company’s stock valued at $93,000 after buying an additional 453 shares during the period. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated.

Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway.